iiinova — where your digital self keeps evolving

Reposted by James Janopaul-Naylor

Mark Cuban @mcuban.bsky.social · 14/03/2025

We don't spend a penny on marketing. It's all word of mouth for @costplusdrugs.com That's how we keep prices so low. Please spread the word !

979340439077 0

Reposted by James Janopaul-Naylor

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 15/02/2025

On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social

0133 0

James Janopaul-Naylor @jjnaylor.bsky.social · 13/02/2025

No discussion of salvage therapies for post-RT failure is complete without reirradiation. Still much to figure out, but great work so far highlighting differences b/w focal and whole gland treatment, pt selection (avoid whole gland for prior brachy). Highly educational #GU25 session

020 0

James Janopaul-Naylor @jjnaylor.bsky.social · 13/02/2025

Excellent nuances at #GU25 on differences in focal approaches for salvage therapy of local recurrence after prostate radiotherapy

021 0

James Janopaul-Naylor @jjnaylor.bsky.social · 13/02/2025

Great discussion of salvage options for local failure after prostate radiotherapy. Particularly consider surgery for seminal vesicle recurrence with potential low morbidity. #ASCO #ASCOGU

010 0

James Janopaul-Naylor @jjnaylor.bsky.social · 10/02/2025

Thanks for having us! Dr Garant and Dr Moningi led high-yield talks about SBRT for RCC and bladder preservation for residents and those prepping for oral boards. Great to hear some of the variability in managing these and locally recurrent prostate cancer. #cansky #oncsky #medsky #MedEd

030 0

James Janopaul-Naylor @jjnaylor.bsky.social · 30/01/2025

My go to when insurance denies routine medications for my patients with prostate cancer. Every time I check it’s a very affordable (sometimes <$5) on cost plus drugs. Full disclosure I get nothing for endorsing them. It really is just great.

010 0

Reposted by James Janopaul-Naylor

Tatiana Prowell, MD @tmprowell.bsky.social · 29/12/2024

President #JimmyCarter died today at age 100, having lived w/ #melanoma that had spread to his brain & liver for >9y. I grew up in GA admiring him, so as an oncologist, I’d like to honor his life by teaching a bit. #melsm #MedSky #OncSky #MedEd First, the ⚠️ signs (ABCDE 👇) & some examples: /1

21341132 0

James Janopaul-Naylor @jjnaylor.bsky.social · 30/11/2024

FWIW I trained at Emory where we routinely used 5mm from cavity/T1+ for 60 Gy volume. Still saw toxicity…

120 0

James Janopaul-Naylor @jjnaylor.bsky.social · 30/11/2024

Or is toxicity driven more by tumor/local recurrences (>80% of time whether you use 5mm or 20mm) and biological differences in sensitivity to 60 Gy with less volumetric affect. That said we certainly could do better from 🧠QoL assessments

230 0

Reposted by James Janopaul-Naylor

ThanksCancer @thankscancer.bsky.social · 16/11/2024

Let’s talk about Cansky hashtags! ⚠️‼️hashtag all posts‼️⚠️ if want to be picked up by our feeds and the larger cancer conversations. If you want to scream into the void, or talk only to your followers, don’t use our hashtags. If you want to scream *with* us, tag us: #Cansky #Oncosky #CancerBS

2816737 0

James Janopaul-Naylor @jjnaylor.bsky.social · 29/11/2024

Pts were excluded “if after radical prostatectomy they were considered by the investigator to be a candidate for salvage radiation therapy”. Hard to extrapolate omission from this dif pop… Want +MFS/OS w/PORT: S8794. What’s the cost of enza and would men rather yrs ADT or 5wk RT (w/o ADT for many).

161 0

Reposted by James Janopaul-Naylor

Razvan Borza @rborza.bsky.social · 23/11/2024

🚨 If you haven’t seen it yet… 📢 The NIH BioArt Source provides a library of FREE professionally designed illustrations and icons, available for anyone to use. They can be Downloaded in High Definition. Check it out at bioart.niaid.nih.gov

415458 0

Reposted by James Janopaul-Naylor

IJROBP @ijrobp.bsky.social · 24/11/2024

Surprised this article hasn't gotten more 👀 Inappropriate Denials for Radiation Therapy in Medicare Advantage Plans www.redjournal.org/article/S036... "These data warrant urgent policy changes to prevent Medicare-eligible patients from being inappropriately denied access to cancer treatments."

redjournal.org

DEFINE_ME

012 0

Reposted by James Janopaul-Naylor

Ananya Choudhury @achoud72.bsky.social · 24/11/2024

Systematic review of radiosensitisation with bladder preserving radiotherapy. ➡️ Use a radiosensitiser wherever possible, doesn't matter which one ➡️ Highest level of evidence for #BCON & #5FUMMC 👏🏽👏🏽👏🏽👇🏽 www.sciencedirect.com/science/arti...

sciencedirect.com

Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials

For selected patients with muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) incorporating transurethral resection of the tumor and chemor…

0229 0

Reposted by James Janopaul-Naylor

Kelly Shanahan @stage4kelly.bsky.social · 23/11/2024

Dear @bsky.app @support.bsky.team, Pretty please can we have a bookmark/save feature? Thank you, #oncsky #advocates #bcsm

4378 0

James Janopaul-Naylor @jjnaylor.bsky.social · 17/11/2024

Thanks for making and please add me

020 0